Amneal Pharmaceuticals was founded in Paterson, New Jersey in 2002 by the Patel family, whose ambition was to achieve entrepreneurial success through hard work and determination.
Jointly led by Chintu and Chirag Patel, Amneal has quickly grown to become a formidable player in the generics industry through strategic acquisitions and significant investments in research, manufacturing and distribution capabilities. The continuous reinvestment in the business and ability to attract talented people allowed the company to develop strong in-house capabilities in research and manufacturing, particularly focused on high barrier-to-entry products such as transdermals, injectibles, inhalation, and topical products. The company’s product portfolio now includes 118 U.S. FDA-approved molecules with another 198 in development, in addition to 115 pending approval.
Today, Amneal ranks as the seventh generic manufacturer in the United States, by prescription volume, and is the fastest-growing global generics company. The company now has more than 4,000 employees with offices in Australia, Europe and Asia. As Amneal continues to experience unprecedented growth, its focus on quality, superb service levels, and building strong relationships holds firm and stands as testament to the strength of its reputation.
Amneal Pharmaceuticals is a member of the Amneal Alliance – a dynamic group of progressive and independent companies leveraging their expertise and resources to bring pioneering healthcare technologies to prevent and treat life-threatening medical conditions. Other members of the Amneal Alliance include Asana Biosciences, Kashiv Pharmaceuticals, Prolong Pharmaceuticals and Therapeutic Proteins International.